Article Details
Retrieved on: 2021-02-09 16:35:20
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The choice at that time is [between] a monoclonal antibody in combination with a newer immunomodulatory drug [IMiD] or a proteasome inhibitor [PI].
Article found on: www.onclive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here